Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignancy in systemic lupus erythematosus

M Abu-Shakra1, D D Gladman, M B Urowitz

  • 1University of Toronto Lupus Clinic, Ontario, Canada.

Arthritis and Rheumatism
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Declining levels of serum chemokine (C-X-C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?

The British journal of dermatology·2020
Same author

Disease course patterns in systemic lupus erythematosus.

Lupus·2018
Same author

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Arthritis research & therapy·2018
Same author

Incidence and variables associated with short and long-term mortality in patients with systemic lupus erythematosus and sepsis admitted in intensive care units.

Lupus·2018
Same author

Severe brady-arrhythmias in systemic lupus erythematosus: prevalence, etiology and associated factors.

Lupus·2018
Same author

Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies.

Lupus·2018
Same journal

Proceedings of the Annual Meeting of the American Rheumatism Association.

Arthritis and rheumatism·2020
Same journal

The regional distribution of rheumatologists: what can we do, what should we do?

Arthritis and rheumatism·2013
Same journal

Regional distribution of adult rheumatologists.

Arthritis and rheumatism·2013
Same journal

Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome.

Arthritis and rheumatism·2013
Same journal

Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study.

Arthritis and rheumatism·2013
Same journal

Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.

Arthritis and rheumatism·2013
See all related articles

Patients with systemic lupus erythematosus (SLE) have a lower overall cancer risk than those with rheumatoid arthritis or systemic sclerosis. However, SLE patients face an increased risk of non-Hodgkin

Area of Science:

  • Rheumatology
  • Oncology
  • Epidemiology

Background:

  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease.
  • Cancer risk in SLE patients requires further investigation.
  • Comparative cancer risk with other autoimmune conditions is not well-established.

Purpose of the Study:

  • To determine the overall and specific cancer risks in patients diagnosed with SLE.
  • To compare cancer incidence in SLE patients with the general population and other autoimmune diseases.

Main Methods:

  • Prospective cohort study of 724 SLE patients over 24 years.
  • Cancer diagnoses confirmed via histologic or autopsy reports.
  • Standardized incidence ratios (SIR) used to compare observed vs. expected cancer rates.

Related Experiment Videos

Main Results:

  • Overall cancer risk was not elevated in SLE patients (SIR 1.08).
  • A 4.1-fold increased risk of hematologic cancers, primarily non-Hodgkin's lymphoma, was observed.
  • SLE patients had a significantly lower cancer risk compared to rheumatoid arthritis and systemic sclerosis cohorts.

Conclusions:

  • Systemic lupus erythematosus (SLE) is linked to a reduced risk of overall cancer compared to rheumatoid arthritis and systemic sclerosis.
  • SLE patients exhibit an elevated risk for non-Hodgkin's lymphoma relative to the general population.